Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN)
详细信息 查看全文
- 作者：Chris Lourens (1)
William M Watkins (1) (3)
Karen I Barnes (1) (4)
Carol H Sibley (1) (5)
Philippe J Guerin (1) (3)
Nicholas J White (1) (2) (3)
Niklas Lindegardh (1) (2) (3) - 刊名：Malaria Journal
- 出版年：2010
- 出版时间：December 2010
- 年：2010
- 卷：9
- 期：1
- 全文大小：608KB
- 参考文献：1. WWARN - World-wide antimalarial resistance network [http://www.wwarn.org]
2. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ: Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. / Clin Pharmacol Ther 2006, 80:582鈥?96. CrossRef
3. Tarning J, McGready R, Lindegardh N, Ashley EA, Pimanpanarak M, Kamanikom B, Annerberg A, Day NP, Stepniewska K, Singhasivanon P, White NJ, Nosten F: Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. / Antimicrob Agents Chemother 2009, 53:3837鈥?846. CrossRef
4. McGready R, Stepniewska K, Lindegardh N, Ashley EA, La Y, Singhasivanon P, White NJ, Nosten F: The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. / Eur J Clin Pharmacol 2006, 62:1021鈥?031. CrossRef
5. Karunajeewa HA, Salman S, Mueller I, Baiwog F, Gomorrai S, Law I, Page-Sharp M, Rogerson S, Siba P, Ilett KF, Davis TM: Pharmacokinetics of chloroquine and mono-desethylchloroquine in pregnancy. / Antimicrob Agents Chemother 2010, 54:1186鈥?192. CrossRef
6. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ: Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. / Antimicrob Agents Chemother 2000, 44:697鈥?04. CrossRef
7. Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ: Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. / Antimicrob Agents Chemother 2000, 44:3414鈥?424. CrossRef
8. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJ, Krishna S, White NJ, Nosten F: Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. / Clin Infect Dis 2006, 42:1570鈥?577. CrossRef
9. Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HL, Kenangalem E, Lindegardh N, Penttinen P, Laihad F, Ebsworth EP, Anstey NM, Tjitra E: Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. / Antimicrob Agents Chemother 2007, 51:4090鈥?097. CrossRef
10. Bacon DJ, Jambou R, Fandeur T, Le Bras J, Wongsrichanalai C, Fukuda MM, Ringwald P, Sibley CH, Kyle DE: World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. / Malar J 2007, 6:120. CrossRef
11. Sibley CH, Barnes KI, Watkins WM, Plowe CV: A network to monitor antimalarial drug resistance: a plan for moving forward. / Trends Parasitol 2008, 24:43鈥?8. CrossRef
12. Barnes KI, Lindegardh N, Ogundahunsi O, Olliaro P, Plowe CV, Randrianarivelojosia M, Gbotosho GO, Watkins WM, Sibley CH, White NJ: World Antimalarial Resistance Network (WARN) IV: clinical pharmacology. / Malar J 2007, 6:122. CrossRef
13. The International Harmonized Protocol for the Proficiency testing of Analytical Chemistry Laboratories / Pure Appl Chem 2006, 78:145鈥?96.
14. Vander Heyden Y, Smeyers-Verbeke J: Set-up and evaluation of interlaboratory studies. / J Chromatogr A 2007, 1158:158鈥?67. CrossRef
15. Quartz - Forensic blood toxicology proficiency testing scheme / LGC Standards Proficiency Testing
16. Hund E, Massart DL, Smeyers-Verbeke J: Inter-laboratory studies in analytical chemistry. / Analytica Chimica Acta 2000, 423:145鈥?65. CrossRef
17. Laboratory Accreditation Program (LAP) Proficiency Testing Response Requirements and Definitions / The College of American Pathologists (CAP)
18. Viswanathan CT: Regulatory observations in bioanalytical determinations. / Bioanalysis 2010, 2:1325鈥?329. CrossRef - 作者单位：Chris Lourens (1)
William M Watkins (1) (3)
Karen I Barnes (1) (4)
Carol H Sibley (1) (5)
Philippe J Guerin (1) (3)
Nicholas J White (1) (2) (3)
Niklas Lindegardh (1) (2) (3)
1. Worldwide Antimalarial Resistance Network (WWARN), Oxford, UK
3. Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
4. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
5. Department of Genome Sciences, University of Washington, Seattle, WA, USA
2. Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
文摘
Background The Worldwide Antimalarial Resistance Network (WWARN) is a global collaboration to support the objective that anyone affected by malaria receives effective and safe drug treatment. The Pharmacology module aims to inform optimal anti-malarial drug selection. There is an urgent need to define the drug exposure - effect relationship for most anti-malarial drugs. Few anti-malarials have had their therapeutic blood concentration levels defined. One of the main challenges in assessing safety and efficacy data in relation to drug concentrations is the comparability of data generated from different laboratories. To explain differences in anti-malarial pharmacokinetics in studies with different measurement laboratories it is necessary to confirm the accuracy of the assay methods. This requires the establishment of an external quality assurance process to assure results that can be compared. This paper describes this process. Methods The pharmacology module of WWARN has established a quality assurance/quality control (QA/QC) programme consisting of two separate components: 1. A proficiency testing programme where blank human plasma spiked with certified reference material (CRM) in different concentrations is sent out to participating bioanalytical laboratories. 2. A certified reference standard programme where accurately weighed amounts of certified anti-malarial reference standards, metabolites, and internal standards are sent to participating bioanalytical and in vitro laboratories. Conclusion The proficiency testing programme is designed as a cooperative effort to help participating laboratories assess their ability to carry out drug analysis, resolve any potential problem areas and to improve their results - and, in so doing, to improve the quality of anti-malarial pharmacokinetic data published and shared with WWARN. By utilizing the same source of standards for all laboratories, it is possible to minimize bias arising from poor quality reference standards. By providing anti-malarial drug standards from a central point, it is possible to lower the cost of these standards.